- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03366493
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. The main purpose of this product is to detect abnormal cervical lesions (CIN2+) during a gynecological speculum examination. Therefore, the purpose of this study is to evaluate the clinical performance of Folate Receptor-Mediated Epithelium Staining (FRDTM) in detecting cervical neoplastic lesions (CIN2+).
The subjects who are enrolled in this study will first undergo the FRD test, then cytology and HPV test. Women with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will have to complete an ECC procedure as well. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion. Subjects can exit the study at any time after colposcopy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Daron G Ferris, MD
- Phone Number: 706-721-2535
- Email: DFERRIS@augusta.edu
Study Contact Backup
- Name: Mena Farag, MS
- Phone Number: 908-668-776
- Email: mena@gy-biotech.com
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Augusta University
-
Contact:
- Angela Goebel, BS, CCRC
- Phone Number: 706-721-8944
- Email: AGOEBEL@augusta.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis: Patients who need to do gynecological pelvic examination
- Age and sex: Women between the ages of 20 - 65
Exclusion Criteria:
- Women with total hysterectomy
- Women who have done cervical surgeries, including physiotherapy of conization, LEEP, infrared ray, and microarray
- Women with serious cervical contact bleeding
- Women who are pregnant or menstrual period before the examination
- Women with acute inflammation of cervix and/or vagina
- Women who were already diagnosed with CIN2+
- Women who are taking an oral and/or injection of anti-cancer drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FRD, Cyctology, HPV testing
Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
|
The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases.
After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator.
After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes.
The physician will then remove any excess stain from the cervix using distilled water.
Other Names:
Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
Other Names:
HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
|
Experimental: Colposcopy Examination (and ECC if necessary)
Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy.
Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure.
In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
|
During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix.
The vinegar solution causes any potential abnormal cells to turn white.
These white regions are best seen using the colposcope, which magnifiesthe skin.
If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC.
This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area.
The sample will be sent to the laboratory for a pathologist to review.
Other Names:
|
Experimental: Biospy
According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken.
Finally, a histopathological examination will be done and used as the gold standard.
Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
|
According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken. Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects diagnosed with CIN2+
Time Frame: 2-4 weeks
|
The primary outcome measure of the study is when the subjects' histological diagnosis is CIN2+.
At that point they can exit the study.
|
2-4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects without CIN2+ after colposcopy
Time Frame: 6 months - 1 year
|
The secondary outcome measures are all women < 25 years & women ≥25 years that were not chosen to be a part of the 10% with normal cytology, negative FRD, & negative HPV. Women without CIN2+ after colposcopy will have to come back for a follow up visit in 6 months or 1 year.
All patients can exit the study after colposcopy.
|
6 months - 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daron G Ferris, MD, Augusta University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GYFRD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia Grade 2/3
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
Tampere UniversityEuropean Union; Academy of Finland; Cancer Society of FinlandActive, not recruitingCervical Intraepithelial Neoplasia Grade 2/3Finland
-
Asieris MediTech (Hong Kong) Co., Ltd.Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3China
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Carcinoma | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical CancerUnited States
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionEnrolling by invitationCervical Intraepithelial Neoplasia Grade 2/3 | Adenocarcinoma in SituFinland
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
ViMREX GmbHFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus...Active, not recruitingVulvar Intraepithelial Neoplasia Grade 2 | Vulvar Intraepithelial Neoplasia Grade 3Germany
-
Marc ArbynUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; University Hospital... and other collaboratorsActive, not recruitingCervical Intraepithelial Neoplasia Grade 2/3Belgium